Individualized cancer therapy

Overall less than 50 percent of patients benefit from their cancer treatment, but the secondary effects apply to all patients.

For the first time, in our clinical studies we have been able to prove that

  • a powerful interaction exists between the p53 gene and numerous chemotherapeutic substances.
  • This means that the efficacy of many cancer therapies is positively or negatively influenced, depending upon the gene status of the individual tumor.

Based upon our clinical research results, we have standardized the p53 gene test and optimized it for routine clinical application. With the aid of this MARK53 analysis, it is now possible to determine the p53 gene status of practically every tumor material and, as a consequence, conclusions are drawn on the expected efficacy of a chemotherapy and radiotherapy.


Univ. Prof. Dr. Daniela Kandioler explained the new findings in a television-interview on private-TV “Schau TV”.

Watch the video